Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCT05779241 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: LYN-005
DRUG: Risperidone

Sponsor

Lyndra Inc.